- Home
- MRNA vs MBLY Comparison
MRNA vs MBLY Comparison
Compare MRNA & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- MBLY
- Stock Information
- Founded
- MRNA 2010
- MBLY 1999
- Country
- MRNA United States
- MBLY Israel
- Employees
- MRNA 5800
- MBLY N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- MBLY Computer Software: Prepackaged Software
- Sector
- MRNA Health Care
- MBLY Technology
- Exchange
- MRNA Nasdaq
- MBLY Nasdaq
- Market Cap
- MRNA 10.3B
- MBLY 11.8B
- IPO Year
- MRNA 2018
- MBLY 2022
- Fundamental
- Price
- MRNA $25.90
- MBLY $14.72
- Analyst Decision
- MRNA Hold
- MBLY Buy
- Analyst Count
- MRNA 19
- MBLY 20
- Target Price
- MRNA $48.13
- MBLY $19.33
- AVG Volume (30 Days)
- MRNA 10.5M
- MBLY 3.1M
- Earning Date
- MRNA 07-31-2025
- MBLY 07-31-2025
- Dividend Yield
- MRNA N/A
- MBLY N/A
- EPS Growth
- MRNA N/A
- MBLY N/A
- EPS
- MRNA N/A
- MBLY N/A
- Revenue
- MRNA $3,177,000,000.00
- MBLY $1,853,000,000.00
- Revenue This Year
- MRNA N/A
- MBLY $8.77
- Revenue Next Year
- MRNA $9.87
- MBLY $16.40
- P/E Ratio
- MRNA N/A
- MBLY N/A
- Revenue Growth
- MRNA N/A
- MBLY N/A
- 52 Week Low
- MRNA $23.15
- MBLY $10.48
- 52 Week High
- MRNA $138.07
- MBLY $28.73
- Technical
- Relative Strength Index (RSI)
- MRNA 46.10
- MBLY 40.57
- Support Level
- MRNA $25.06
- MBLY $15.75
- Resistance Level
- MRNA $28.72
- MBLY $16.90
- Average True Range (ATR)
- MRNA 1.18
- MBLY 0.68
- MACD
- MRNA -0.18
- MBLY -0.23
- Stochastic Oscillator
- MRNA 20.34
- MBLY 3.91
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.